Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform^™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights.